New drug trial targets Tough-to-Treat kidney disease
NCT ID NCT07234474
Summary
This is a first-in-human study to test the safety and initial effects of an experimental drug called YK012. It is for adults with a severe form of primary membranous nephropathy, a serious kidney disease, who have not responded to other available treatments. The main goal is to find a safe dose and see how the body handles the drug, while also checking for early signs that it might help control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.